147 studies found for:
Emtricitabina/ Fumarato de disoproxilo de tenofovir OR Truvada[TREATMENT] AND HIV [CONDITION]
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Completed |
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
|
||||
| 2 | Completed |
Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
|
||||
| 3 |
Completed
Has Results |
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
|
||||
| 4 |
Completed
Has Results |
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
|
||||
| 5 | Completed |
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
|
||||
| 6 | Completed |
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
|
||||
| 7 |
Completed
Has Results |
Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM)
|
||||
| 8 | Active, not recruiting |
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
|
||||
| 9 | Completed |
Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)
|
||||
| 10 | Completed |
A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP
|
||||
| 11 |
Active, not recruiting
Has Results |
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
|
||||
| 12 |
Completed
Has Results |
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
|
||||
| 13 | Recruiting |
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
|
||||
| 14 | Active, not recruiting |
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
|
||||
| 15 | Active, not recruiting |
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
|
||||
| 16 | Recruiting |
A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)
|
||||
| 17 | Completed |
Combination of Efavirenz and Truvada - COMET Study
|
||||
| 18 | Completed |
GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance
|
||||
| 19 | Unknown † |
Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
|
||||
| 20 |
Completed
Has Results |
A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
|
† Indicates status has not been verified in more than two years
